Kuromanin

Kuromanin

SCHEMBL316825

OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@H]1O.[Cl-]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Kuromanin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.98
CD38 P28907 2/20 0.98
F2 P00734 2/20 0.87
SNCA P37840 1/20 0.52
GLO1 Q04760 1/20 0.52
KDM4E B2RXH2 4/20 0.51
GAA P10253 4/20 0.51
AKR1B1 P15121 4/20 0.51
MAPT P10636 3/20 0.51
POLB P06746 2/20 0.51
P4HB P07237 2/20 0.51
EPHX2 P34913 2/20 0.51
ADRA2C P18825 1/20 0.51
NOX4 Q9NPH5 1/20 0.51
CA12 O43570 1/20 0.51
KDM1A O60341 1/20 0.51
SLCO2B1 O94956 1/20 0.51
CA2 P00918 1/20 0.51
ALPL P05186 1/20 0.51
HMGB1 P09429 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kuromanin SCHEMBL29762023 1.00 DPP4 (0.98) DPP4CD38F2SNCAGLO1
Kuromanin SCHEMBL29377806 1.00 DPP4 (0.98) DPP4CD38F2SNCAGLO1
Kuromanin SCHEMBL440823 1.00 DPP4 (0.98) DPP4CD38F2SNCAGLO1
Kuromanin SCHEMBL158216 1.00 DPP4 (0.98) DPP4CD38F2SNCAGLO1
Kuromanin SCHEMBL29349461 1.00 DPP4 (0.98) DPP4CD38F2SNCAGLO1
Kuromanin SCHEMBL3765133 0.99 DPP4 (0.96) DPP4CD38F2SNCAGLO1
Kuromanin SCHEMBL625949 0.99 DPP4 (0.96) DPP4CD38F2SNCAGLO1
Kuromanin SCHEMBL288591 0.99 CD38 (1.00) DPP4CD38F2SNCAGLO1
Kuromanin SCHEMBL1097555 0.99 CD38 (1.00) DPP4CD38F2SNCAGLO1
Kuromanin SCHEMBL1096430 0.99 CD38 (1.00) DPP4CD38F2SNCAGLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
EP-2976061-B1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS DENTALMED PHARM HOLDING LTD (BE) 2019-10-16 EP claimed
US-20160279043-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS DENTALMED PHARM HOLDING LTD. (BE) 2016-09-29 US claimed
EP-2976061-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS Dentalmed Pharm Holding Ltd. (BE) 2016-01-27 EP claimed
WO-2014147613-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS DENTALMED PHARM HOLDING LTD. (BE) 2014-09-25 WO claimed
CN-102245177-A Oral composition UNILEVER NV 2011-11-16 CN claimed
WO-2011130719-A2 A BIOSYNTHETIC PATHWAY FOR HETEROLOGOUS EXPRESSION OF A NONRIBOSOMAL PEPTIDE SYNTHETASE DRUG AND ANALOGS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-10-20 WO claimed
US-20110237660-A1 ORAL COMPOSITION CONOPCO, INC., D/B/A UNILEVER 2011-09-29 US claimed
EP-2365807-A1 ORAL COMPOSITION Unilever PLC (GB) 2011-09-21 EP claimed
US-7887868-B2 low-salt soy sauce having an antihypertensive effect; contains 3.55% or less by weight of sodium, 0.5% to 3.6% by weight of potassium, 0.05 to 20% by weight of at least one polyphenol KAO CORPORATION (JP) 2011-02-15 US claimed
WO-2010066641-A1 ORAL COMPOSITION UNILEVER PLC (GB) 2010-06-17 WO claimed
US-7727524-B2 Low sodium liquid seasoning with anti-hypertensive activity KAO CORPORATION (JP) 2010-06-01 US claimed
CN-2433670-Y Physical isolator suitable for computer network LIANG YANWEN (CN) 2001-06-06 CN claimed
EP-0496349-B1 Coating solution for preventing adhesion of polymer scale and method for its use SHINETSU CHEMICAL CO (JP) 1996-04-10 EP claimed
EP-0496349-A1 Coating solution for preventing adhesion of polymer scale and method for its use SHIN-ETSU CHEMICAL CO., LTD. (JP) 1992-07-29 EP claimed
WO-2025070135-A1 HEXAVALENT-CHROMIUM-REDUCING PHOTOCATALYST COMPOSITION AND METHOD FOR REDUCING HEXAVALENT CHROMIUM ユシロ化学工業株式会社 2025-04-03 WO disclosed
CN-113881685-B Gene PpHSP20-like1 for promoting plant organ to produce red color and application thereof 江苏省农业科学院 2024-03-29 CN disclosed
US-5241022-A Polyvinyl alcohol with saponification of not less than seventy percent and quinone SHIN-ETSU CHEMICAL CO., LTD. (JP) 1993-08-31 US disclosed
EP-0496349-A1 Coating solution for preventing adhesion of polymer scale and method for its use SHIN-ETSU CHEMICAL CO., LTD. (JP) 1992-07-29 EP disclosed
EP-0397879-A1 METHOD FOR DETECTING GLYCOSIDICALLY LINKED LOW-MOLECULAR COMPOUND BY IMMUNOASSAY P.C.C. TECHNOLOGY INC. (JP) 1990-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160279043-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS SIRT3, NNT, SIRT1 DPP4 866/4885CD38 253/4885F2 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.